TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Brief Summary: This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).


Options:
A: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Brief Summary: This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2
B: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo
C: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adapting Tools to Implement Stroke Risk Management to Veterans
Brief Summary: The purpose of this study is to develop and evaluate the local adaptation of existing stroke prevention tools into practice. A stroke prevention program is a collection of materials including written materials like pamphlets and brochures, videotapes and training guides for stroke survivors and evidence based guidelines for the doctors that provide care for them. Other tools that may be used in a stroke prevention program include devices that help patients monitor medical symptoms at home like home blood pressure machines or blood sugar monitors and messaging devices that allow reporting symptoms from home to a health care provider.

We hypothesized Veterans with stroke who receive the Veteran Stroke Prevention Program would engage in better medication compliance and stroke specific quality of life compared to those who did not receive the program.


Options:
A: Arm Label: Arm 1 Secondary Risk Factor Management; Type: EXPERIMENTAL; Interventions: Behavioral: Physician stroke guideline adherence, Behavioral: Stroke Self Management | Arm Label: Attention Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Attention Control Group | Intervention Type: BEHAVIORAL; Name: Physician stroke guideline adherence; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: BEHAVIORAL; Name: Stroke Self Management; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: OTHER; Name: Attention Control Group; Assigned to Arm(s): Attention Control Group
B: Arm Label: Post-discharge phone call; Type: N/A; Interventions: N/A | Arm Label: Usual care (no phone call); Type: N/A; Interventions: N/A
C: Arm Label: Medication therapy management; Type: EXPERIMENTAL; Interventions: Other: Medication therapy management | Intervention Type: OTHER; Name: Medication therapy management; Assigned to Arm(s): Medication therapy management
D: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adapting Tools to Implement Stroke Risk Management to Veterans
Brief Summary: The purpose of this study is to develop and evaluate the local adaptation of existing stroke prevention tools into practice. A stroke prevention program is a collection of materials including written materials like pamphlets and brochures, videotapes and training guides for stroke survivors and evidence based guidelines for the doctors that provide care for them. Other tools that may be used in a stroke prevention program include devices that help patients monitor medical symptoms at home like home blood pressure machines or blood sugar monitors and messaging devices that allow reporting symptoms from home to a health care provider.

We hypothesized Veterans with stroke who receive the Veteran Stroke Prevention Program would engage in better medication compliance and stroke specific quality of life compared to those who did not receive the program.


Options:
A: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Smart-phone based technology | Arm Label: Usual background care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smart-phone based technology; Assigned to Arm(s): Behavioral
B: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
C: Arm Label: Regular care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Support program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient centered structured support program | Intervention Type: BEHAVIORAL; Name: Patient centered structured support program; Assigned to Arm(s): Support program
D: Arm Label: Arm 1 Secondary Risk Factor Management; Type: EXPERIMENTAL; Interventions: Behavioral: Physician stroke guideline adherence, Behavioral: Stroke Self Management | Arm Label: Attention Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Attention Control Group | Intervention Type: BEHAVIORAL; Name: Physician stroke guideline adherence; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: BEHAVIORAL; Name: Stroke Self Management; Assigned to Arm(s): Arm 1 Secondary Risk Factor Management | Intervention Type: OTHER; Name: Attention Control Group; Assigned to Arm(s): Attention Control Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)
Brief Summary: Title: SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI).

Study population: Patients with acute myocardial infarction, treated with primary PCI.

Objective: To determine whether intracoronary infusion of BMCs improves recovery of left ventricular function after acute myocardial infarction treated by PCI

Design: Multi-center, randomized, controlled clinical trial with central core lab analysis for MRI.

Therapy: Intracoronary infusion of BMCs in the infarct related artery at 5-7 days or 3-4 weeks after successful primary PCI

Primary Endpoint: Change in global left ventricular ejection fraction (LVEF) at 4 months relative to baseline measured by quantitative MRI.

Secondary Endpoints:

* Change in LVEF at MRI at 12 months
* Change in regional left ventricular wall motion and thickness at 4 and 12 months.
* Change in infarct size at 4 and 12 months as assessed by "delayed enhancement" technique by MRI
* Analysis of the myocardial infarct size and transmurality, time to PCI and coronary flow characteristics after PCI as predictor of LV remodeling and change after cell therapy
* Change in myocardial perfusion at 4 and 12 months
* Change in serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)
* Major adverse cardiac events (MACE: death, myocardial infarction, TVR (ACBP or PCI, stroke, hospitalization for cardiac reasons) at 12 months

Interventions:

* Aspiration of 50 ml bone marrow (\<24 hours) prior to administration
* Intracoronary balloon-based infusion of 10 ml BMCs
* Cardiac MRI at baseline (resp. at hospital discharge), at 4 and 12 months

Therapy groups: Bone marrow-derived stem cells infusion in the successfully revascularized infarct related vessel at day 5-7 or day 21-28.

Control group: Management according to the "state of the art" medical therapy after successful primary PCI.

Safety: A study independent "safety committee" will analyze the clinical results after the first 60 patients.


Options:
A: Intervention Type: GENETIC; Name: Intracoronary aotologous stem cell transplantation; Assigned to Arm(s): N/A
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Intra-coronary infusion | Intervention Type: DRUG; Name: Intra-coronary infusion; Assigned to Arm(s): Treatment Group
C: Intervention Type: PROCEDURE; Name: cd133+cell intracoronary administration; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Arm Label: Late; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Intervention Type: PROCEDURE; Name: intracoronary bone marrow cells infusion; Assigned to Arm(s): Early, Late

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Brief Summary: The purpose of this study is to determine the safety and efficacy of sirolimus-based immunosuppressive therapy in patients following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), with regard to HCC recurrence-free patient survival.


Options:
A: Intervention Type: DRUG; Name: ATG (Fresenius Biotech); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2
C: Arm Label: 1 Drug:; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus + steroid | Arm Label: 2 Drug:; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus + mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus + steroid; Assigned to Arm(s): 1 Drug: | Intervention Type: DRUG; Name: tacrolimus + mycophenolate mofetil; Assigned to Arm(s): 2 Drug:
D: Arm Label: EVR/TAC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: TAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): EVR/TAC | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): EVR/TAC, TAC | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR/TAC, TAC

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open Label Randomized Controlled Trial
Brief Summary: The purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in Bangladesh.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin plus Chloroquine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Azithromycin plus Chloroquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): 2
C: Arm Label: 1AZ+AQ; Type: EXPERIMENTAL; Interventions: Drug: azithromycin + artesunate | Arm Label: 2AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: artemether-lumefantrine | Intervention Type: DRUG; Name: azithromycin + artesunate; Assigned to Arm(s): 1AZ+AQ | Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): 2AL
D: Arm Label: Azithromycin + Artesunate; Type: EXPERIMENTAL; Interventions: Drug: azithromycin plus artesunate | Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Intervention Type: DRUG; Name: azithromycin plus artesunate; Assigned to Arm(s): Azithromycin + Artesunate | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25.
Brief Summary: This is a single center trial to compare the rate of surgical site infection (SSI) in normal (BMI equal to or less than 25; Control Group)) and overweight (BMI over 25) women who are undergoing breast cancer surgery. The overweight patients are further randomized into two groups; in one group patients receive prophylactic antibiotics (ampicillin/sulbactam; Prophylaxis Group), in the other they do not (No Prophylaxis Group).


Options:
A: Arm Label: Antibiotics until Drain Removal; Type: OTHER; Interventions: Drug: Cefadroxil until drain removal | Arm Label: Early discontinuation of antibiotics; Type: EXPERIMENTAL; Interventions: Drug: Cefadroxil discontinued early | Intervention Type: DRUG; Name: Cefadroxil discontinued early; Assigned to Arm(s): Early discontinuation of antibiotics | Intervention Type: DRUG; Name: Cefadroxil until drain removal; Assigned to Arm(s): Antibiotics until Drain Removal
B: Arm Label: Gentamicin lavage; Type: EXPERIMENTAL; Interventions: Drug: Axillary lavage with gentamicin solution | Arm Label: Normal saline lavage; Type: ACTIVE_COMPARATOR; Interventions: Drug: Axillary lavage with gentamicin solution | Intervention Type: DRUG; Name: Axillary lavage with gentamicin solution; Assigned to Arm(s): Gentamicin lavage, Normal saline lavage
C: Arm Label: Prophylaxis Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ampicillin/Sulbactam | Arm Label: No Prophylaxis Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Ampicillin/Sulbactam; Assigned to Arm(s): Prophylaxis Group
D: Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cefazolin | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sterile water | Intervention Type: PROCEDURE; Name: Cefazolin; Assigned to Arm(s): Treatment Arm | Intervention Type: PROCEDURE; Name: Sterile water; Assigned to Arm(s): Placebo Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic Sleeve Gastrectomy or Laparoscopic Proximal Roux-Y-gastric Bypass in the Treatment of Morbid Obesity
Brief Summary: The laparoscopic sleeve-gastrectomy (SG) compared to laparoscopic proximal Roux-Y-gastric bypass (PGB) is as successful in the treatment of morbid obesity in the majority of patients. In case of insufficient weight loss malabsorption can to be added by performing laparoscopic bilious-pancreatic diversion duodenal switch (BPD). The resection of the gastric fundus (LG) leads to changes in gastrointestinal hormones that are possibly different to bypassing the fundus (PGB).


Options:
A: Arm Label: Medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Gastric Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Gastric bypass | Arm Label: Sleeve Gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sleeve Gastrectomy | Intervention Type: PROCEDURE; Name: Gastric bypass; Assigned to Arm(s): Gastric Bypass | Intervention Type: PROCEDURE; Name: Sleeve Gastrectomy; Assigned to Arm(s): Sleeve Gastrectomy
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: sleeve gastrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-Y-gastric bypass | Intervention Type: PROCEDURE; Name: sleeve gastrectomy; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Roux-Y-gastric bypass; Assigned to Arm(s): B
C: Arm Label: Bariatric surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery | Arm Label: Intensive lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Bariatric surgery | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
D: Arm Label: EndoBarrier Device; Type: EXPERIMENTAL; Interventions: Device: EndoBarrier Device, Behavioral: Diet & Lifestyle Counseling | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet & Lifestyle Counseling | Intervention Type: DEVICE; Name: EndoBarrier Device; Assigned to Arm(s): EndoBarrier Device | Intervention Type: BEHAVIORAL; Name: Diet & Lifestyle Counseling; Assigned to Arm(s): Control, EndoBarrier Device

Answer: B